Last updated on

Journal of Clinical Oncology
Research Hotspot & Journal Scope - NSCLC


Journal of Clinical Oncology - DOI: 10.1200/JCO.2019.37.15_SUPPL.8503
Neoadjuvant atezolizumab in resectable non-small cell lung cancer (NSCLC): Interim analysis and biomarker data from a multicenter study (LCMC3).

David J. Kwiatkowski · Valerie W. Rusch · Jamie E. Chaft · Bruce E. Johnson · Alan Nicholas · Ignacio Ivan Wistuba · Robert E. Merritt · Jay M. Lee · Paul A. Bunn · Yan Tang · See-Chun Phan · Saiama N. Waqar · Alexander Patterson · Eric B. Haura · Eric M. Toloza · Karen L. Reckamp · Dan J. Raz · Katja Schulze · Ann M. Johnson · David P. Carbone ·

Medicine
PDF
Journal of Clinical Oncology - DOI: 10.1200/JCO.2019.37.15_SUPPL.9000
RELAY: A multinational, double-blind, randomized Phase 3 study of erlotinib (ERL) in combination with ramucirumab (RAM) or placebo (PL) in previously untreated patients with epidermal growth factor receptor mutation-positive (EGFRm) metastatic non-small cell lung cancer (NSCLC).

Kazuhiko Nakagawa · Edward B. Garon · Takashi Seto · Makoto Nishio · Santiago Ponce Aix · Chao-Hua Chiu · Keunchil Park · Silvia Novello · Ernest Nadal · Fumio Imamura · Kiyotaka Yoh · Jin-Yuan Shih · Kwok Hung Au · Denis Moro-Sibilot · Sotaro Enatsu · Annamaria Zimmermann · Bente Frimodt-Moller · Carla M. Visseren Grul · Martin Reck ·

Medicine
PDF
Journal of Clinical Oncology - DOI: 10.1200/JCO.2019.37.15_SUPPL.9017
Spatial and temporal heterogeneity of PD-L1 and its impact on benefit from immune checkpoint blockade in non-small cell lung cancer (NSCLC).

Lingzhi Hong · Seyedeh Dibaj · Marcelo Vailati Negrao · Alexandre Reuben · Emily Roarty · Waree Rinsurongkawong · Jeffrey A. Lewis · Don Lynn Gibbons · Boris Sepesi · Vassiliki A Papadimitrakopoulou · Bonnie S. Glisson · George R. Blumenschein · Phillip Andrew Futreal · Ignacio Ivan Wistuba · Jack A. Roth · Stephen G. Swisher · John Victor Heymach · George R. Simon · Jiun-Kae Jack Lee · Jianjun Zhang ·

Medicine
PDF
Journal of Clinical Oncology - DOI: 10.1200/JCO.2019.37.15_SUPPL.8502
Initial reporting of NRG-LU001 (NCT02186847), randomized phase II trial of concurrent chemoradiotherapy (CRT) +/- metformin in locally advanced Non-Small Cell Lung Cancer (NSCLC).

Theodoros Tsakiridis · Chen Hu · Heath D. Skinner · Rafael Santana-Davila · Bo Lu · Jeremy J. Erasmus · A Doemer · Gregory M.M. Videtic · J. Coster · Xuezhong Yang · Richard J. Lee · Maria Werner-Wasik · Philip E. Schaner · Steven Eric McCormack · Benjamin T. Esparaz · Ronald C. McGarry · Jose G. Bazan · Timothy Struve · Jeffrey D. Bradley ·

Medicine
PDF
Journal of Clinical Oncology - DOI: 10.1200/jco.2019.37.27_suppl.3
Effect of high patient out-of-pocket (OOP) cost for oral tyrosine kinase inhibitors (TKIs) on survival in EGFR and ALK positive stage IV non-small cell lung cancer (NSCLC).

Bernardo H. L. Goulart · Joseph M. Unger · Shasank Chennupati · Kathryn Egan · Catherine R. Fedorenko · Scott D. Ramsey ·

Medicine
PDF

Here, we evaluated multiple metrics of circulating tumor DNA (ctDNA) for association with OS in the Ph3 OAK study, which demonstrated clinically significant OS benefit in ≥ 2L NSCLC patients treated with atezolizumab vs docetaxel.

An exploratory analysis of on-treatment ctDNA measurement as a potential surrogate for overall survival for atezolizumab benefit in the OAK study [10.1093/annonc/mdz260.081]


PATIENTS AND METHODS Society of Thoracic Surgeons outcomes data and surveillance records of patients with stage I-IIIa NSCLC who had undergone lobectomy by robotic-assisted, VATS, or the open approach at a single center from 2012 to 2017 were reviewed.

Long-Term Oncologic Outcomes After Robotic Lobectomy for Early-stage Non-Small-cell Lung Cancer Versus Video-assisted Thoracoscopic and Open Thoracotomy Approach. [10.1016/j.cllc.2019.10.004]


Therefore, exosomes can be a useful source of biomarkers in NSCLC analysis.

Exosomes in NSCLC as a source of biomarkers [10.1093/annonc/mdz268.051]


Despite advances in research and a better understanding of the molecular pathways of NSCLC, few effective therapeutic options are available for most patients with NSCLC without druggable targets, especially for patients with squamous cell NSCLC.

Current status of immune checkpoint inhibitors in treatment of non-small cell lung cancer [10.3904/kjim.2018.179]


Conclusions The addition of necitumumab to standard chemotherapy in a first-line setting in patients with stage IV NSCLC results in a statistically significant improvement in overall survival, while the results were not significant for progression-free survival and objective response rate.

Effects of adding necitumumab to first-line chemotherapy in patients with stage IV non-small-cell lung cancer: Meta-analysis [10.1177/1078155219891631]



Research Hotspot

Journal of Clinical Oncology

Research Hotspot
Journal of Clinical Oncology Related Journals

Popular Journals